Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07486583
PHASE3

Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.

Sponsor: Cairo University

View on ClinicalTrials.gov

Summary

To evaluate the efficacy of Autologous Whole Blood Therapy versus conventional treatment using fourfold dose of antihistamines in Autologus serum skin test (ASST) positive and negative Chronic Idiopathic Urticaria (CIU) patients and suggest its possible mechanism of action.

Official title: Autologous Whole Blood Therapy in Autologous Serum Skin Test (ASST) Positive and Negative Chronic Idiopathic Urticaria Patients, a Clinical and Biochemical Randomized Controlled Trial.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-04-30

Completion Date

2026-11-30

Last Updated

2026-03-20

Healthy Volunteers

No

Interventions

BIOLOGICAL

Autologous whole blood therapy

The AWBT test group patients will receive 8 doses of autologous whole blood therapy (AWBT) once weekly. The first dose will be 2.5ml and subsequent doses will be 5ml of venous blood, which will be drawn from any accessible vein under aseptic precautions. The blood will be re-injected immediately by deep intramuscular injection (IM) on alternate gluteal regions.

DRUG

Desloratadine

All patients will take desloratadine 10 mg at four-fold dose daily

Locations (1)

Faculty of Medicine, Cairo university

Cairo, Cairo Governorate, Egypt